

BAKER BOTTS LLP



JUL 03 2000

RECEIVED

July 3, 2000

W. AF
TIE WARNER
1299 PENNSYLVANIA AVE., NW
WASHINGTON, DC
20004-2400
202.639.7700
FAX 202.639.7890

Box 509
AUSTIN
BAKU GP1645
DALLAS
HOUSTON
LONDON
MOSCOW
NEW YORK
WASHINGTON

Inventor Patent Application of

LO, et al.

Application No.: 08/753,750

Filed: November 29, 1996

Title: TRANSFERRIN BINDING PROTEINS OF
PASTEURILLA HAEMOLYTICA AND
VACCINES CONTAINING SAME

Attorney Docket No.: 021645.0105

Group Art Unit: 1645

Examiner: N. MINNIFIELD

RECEIVED

JUL 10 2000

BOX AF

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

Transmitted herewith is an amendment in the above-identified application. Fees have been calculated as shown below:

CLAIMS AS AMENDED						
	Claims Remaining After Amendment	Highest Number Previously Paid For	Extra	Rate		Amount
				Large Entity	Small Entity	
Number of Claims in Excess of 20	22	22	0	\$ 18.00	\$ 9.00	\$ 0.00
Independent Claims in Excess of 3	3	3	0	\$ 78.00	\$ 39.00	\$ 0.00
First Presentation of Multiple Dependent Claims				\$ 260.00	\$ 130.00	\$ 0.00
Extension Fee:	a) One Month			\$ 110.00	\$ 55.00	\$ 0.00
	b) Two Months			\$ 380.00	\$ 190.00	
	c) Three Months			\$ 870.00	\$ 435.00	
	d) Four Months			\$1360.00	\$ 680.00	
	e) Five Months			\$1850.00	\$ 925.00	
Other:						\$ 0.00
TOTAL FEE DUE						\$ 0.00

- ☒ No additional fee is required.
☐ A check in the amount of \$ _____ is attached.
☐ Charge \$ _____ to Deposit Account No. 02-0375.
☒ Charge any additional fees or credit any overpayment to Deposit Account No. 02-0375.

- A Verified Statement under 37 C.F.R. §§ 1.9 and 1.27:
☐ is attached.
☒ is of record in this application.

Respectfully submitted,

By:

Laurence H. Posorske
Registration No. 34,698

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of:

LO et al.

Application Number: 08/753,450

Filed: November 29, 1996

For: Transferrin Binding Proteins of
Pasteurella Haemolytica and
Vaccines Containing Same



Group Art Unit: 1645

Examiner: Nita M Minnifield

#19/E 7/10/00
TBray
CNG

Commissioner of Patents
U.S. Patent and Trademark Office
Washington, D.C. 20231

AMENDMENT UNDER 37 C.F.R. §1.116

Sir:

The following amendments are submitted in response to the final Office Action dated March 1, 2000, in the subject application. It is believed that no fees are required to make this response timely; however, should it be determined that fees are required, the Commissioner is authorized to charge such fees to Deposit Account 02-0375.

Please amend the subject application as follows:

In the Sequence Listing

Please delete the Sequence Listing filed on May 2, 1997, pages 81-115, and replace it with the enclosed Sequence Listing, pages 81-107. In accordance with 37 C.F.R. § 1.825, a computer readable form of the Sequence Listing is also enclosed. In accordance with 37 C.F.R. § 1.821(f), undersigned certifies that the information recorded on the computer readable form is identical with the paper copy of the Sequence Listing enclosed herewith.

In the Claims

Please amend claims 30, 43-44, and 46-47 as follows.

30. (Twice Amended) An isolated and purified polynucleotide which hybridizes under stringent conditions to a member selected from the group consisting of:

DO NOT
enter
7-19-00
MM

E1
[Signature]

E